Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. It is not yet known which combination chemotherapy regimen is more
effective for urinary tract cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin plus
gemcitabine with or without paclitaxel in treating patients who have stage IV urinary tract
cancer.
Phase:
Phase 3
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators:
Central European Cooperative Oncology Group German Association of Urologic Oncology Groupe D'Etude des Tumeurs Uro-Genitales Institute of Cancer Research, United Kingdom Medical Research Council National Cancer Institute (NCI) NCIC Clinical Trials Group Southwest Oncology Group Spanish Oncology Genito-Urinary Group